Bicycle Therapeutics (50BA) AI Stock Analysis

1 Followers

Bicycle Therapeutics

(Frankfurt:50BA)

Rating:―N/A

Action:N/A

Date:―

No summary available

Positive Factors

Revenue GrowthImproving revenue indicates increasing contribution from Bicycle’s partnered programs and development activities. Although the company remains clinical-stage, sustained top-line expansion can support pipeline investment and strengthen the platform’s commercial potential over the next several quarters.

Negative Factors

Persistent Operating LossesDeep and persistent operating losses show that Bicycle has not yet achieved a scalable earnings model. Without meaningful operating leverage, continued pipeline advancement will remain dependent on external capital or collaboration economics rather than internally generated profits.

Bicycle Therapeutics (50BA) vs. iShares MSCI Germany ETF (EWG)

Market Cap: EUR 258.65M
Dividend Yield: ―
Average Volume (3M): 775
Price to Earnings (P/E): -1.8
Beta (1Y): 1.30
Revenue Growth: 181.95%
EPS Growth: 46.67%
Country: Germany
Employees: 288
Sector: Healthcare
Sector Strength: 51
Industry: Biotechnology

Bicycle Therapeutics Business Overview & Revenue Model

Company Description

Bicycle Therapeutics plc, founded in 2009 and based in Cambridge, UK, is a clinical-stage biopharmaceutical company. Its core mission is to create innovative therapeutic classes for diseases currently lacking effective treatments. The company's leadi...

Bicycle Therapeutics Risk Analysis

Bicycle Therapeutics disclosed 75 risk factors in its most recent earnings report. Bicycle Therapeutics reported the most risks in the "Tech & Innovation" category.

Tech & Innovation - Risks related to the company’s reliance on technology and ability to make innovative products

Latest Risks Added

0 New Risks

Bicycle Therapeutics Peers Comparison

Overall Rating

UnderperformOutperform

Sector (51)

Financial Indicators

DE:50BA against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
Sector *	51Neutral	$7.86B	-0.30	-43.30%	2.27%	22.53%	-2.21%
ADCT	47Neutral	$192.78M	-3.06	36.95%	―	12.85%	63.71%
MGNX	46Neutral	$154.15M	-10.54	-31.27%	―	1.32%	59.94%
STRO	42Neutral	$168.63M	-0.59	185.30%	―	-56.25%	30.97%
PYXS	41Neutral	$194.96M	-1.26	-252.36%	―	291.42%	18.90%
MOLN	39Underperform	$125.16M	-1.86	-79.25%	―	―	11.22%

* Healthcare Sector Average

Performance Comparison

DE:50BA and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
DE:50BA	Bicycle Therapeutics	3.22	-2.23	-40.92%
MGNX	MacroGenics Inc	2.32	0.72	45.00%
STRO	Sutro Biopharma	10.26	0.97	10.44%
ADCT	ADC Therapeutics Ltd	1.60	-2.45	-60.49%
MOLN	Molecular Partners Ag	3.09	-1.19	-27.80%
PYXS	Pyxis Oncology, Inc.	1.64	-2.84	-63.39%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Bicycle Therapeutics AI Stock Analysis